ZEB2 and non-small cell lung carcinoma: In addition, we found that both miR-6734-3p overexpression and ZEB2 downregulation increased the susceptibility of NSCLC cells to cisplatin stimulation, which were partly supported by the previous data [32,33] and suggested that miR-6734-3p and ZEB2 could be used as potential agents to improve cisplatin-sensitivity for NSCLC treatment in clinic.